期刊文献+

尿激酶原在培养上清液中稳定性的研究

Stability of pro-urokinase in culture supernatant
下载PDF
导出
摘要 目的:探讨尿激酶原糖基化对其表达稳定性的影响。方法:将302位天冬酰胺(A sn302)突变为丙氨酸(A la302),构建非糖基化尿激酶原。用基因重组的方法将重组尿激酶原和天然尿激酶原转染至dh-CHO细胞(二氢叶酸还原酶缺陷型——中国仓鼠卵巢细胞)中培养。收取无血清培养上清为检测标本。用嗜热杆菌的金属蛋白酶(ther-m o lys in)激活尿激酶原。用抑肽酶(aprotin in)终止激活反应。生色底物S-2444用于显色反应。在405nm波长处测定OD值(分光光度值)以确定双链成分的比例。在不用therm o lys in激活的条件下,用公式计算单链尿激酶原比例。将重组尿激酶原和天然尿激酶原的培养上清液置于4℃和37℃。每隔12 h测定总活性和单链成分比例。经过阳离子层析和凝胶层析纯化后,测定蛋白产品浓度、活性。以SDS-PAGE电泳鉴定蛋白质分子量和蛋白含量。结果:在37℃下天然尿激酸原(糖基化)的活性远高于重组尿激酶原(非糖基化)。无论4℃或37℃,糖基化尿激酶原的单链比例均高于非糖基化尿激酶原。纯化后的天然尿激酶原蛋白产品浓度和活性均高于重组尿激酶原。SDS-PAGE电泳结果提示天然尿激酶原浓度高于重组尿激酶原,分子量低于重组尿激酶原。结论:较高的温度加速原激酶原降解。A sn302位的糖基化位点有益于尿激酶原在培养上清液中的稳定性。 Objective: To investigate the effect of glycosylation on the stability of pro-urokinase expression. Methods: Non-glycosylated pro-urokinase was created by Asn302—Ala302 mutagenesis. The recombinant pro—UK and natural pro— UK were transflected into dhfr-CHO cells with gene recombinant technique. Serum-free culture supernatants were harvested for further assessment. Pro—UK was activated by thermolysin. The reaction was stopped by aprotinin. Chromogenic substrate S—2444 was used for chromogenesis. The form OD was measured at 405nm wavelength for detected amount of two-chain. Without thermolysin activation, single chain ratio was calculated with equation. The supernatants of recombinant pro—UK and natural pro—UK were stored at 4 ℃ and incubated at 37 ℃ separately. Total activity and single-chain ratio were detected every 12 hours. The concentrations and activities of pro— UK protein products were measured after ion-exchange chromatography and gel-filtration chromatography purifications. Protein concentration and molecular weight were assessed by SDS—PAGE. Results: The activity of natural pro —UK was much higher than that of non-glycosylated mutant at 37 ℃. The single-chain form of natural pro—UK was higher than those of non-glycosylated mutant at 4℃and 37 ℃. The protein concentration and activity of natural pro— UK were both higher than those of recombinant pro—UK. SDS—PAGE show that the concentration of natural pro—UK was higher than that of recombinant pro—UK and the molecular weight of natural pro—UK was lower than that of recombinant pro—UK. Conclusion: Higher temperature increases the proteolysis of pro—UK. The glycosylation site on Asn302 was benefit for pro—UK stability in culture supernatant.
出处 《心血管康复医学杂志》 CAS 2006年第5期471-475,共5页 Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词 酶稳定性 尿纤溶酶原激活物 糖基化 Enzyme stability Urine plasminogen activator Glycosylation
  • 相关文献

参考文献9

  • 1Grewich V.Pro-urokinase:history,mechanisms of action,and clinical development.In:Loscalzo J,Saashara AA New therapeutic agents in thrombosis and thrombolysis[J].New York:Marcel Dekker,1997,495-511.
  • 2胡显文,高丽华,李世崇,胥照平,张正光,肖成祖,饶春明,张翊,姜燕,胡铁强.发色底物法定量测定重组u-PA产品的总活性和单链比例[J].军事医学科学院院刊,2003,27(5):349-352. 被引量:11
  • 3Furlan AJ,Abou-Chebi A.The role of recombinant pro-urokinase (r-pro-UK) and intra-arterial thrombolysis in acute ischemic stroke:the PROACT trials.Prolyse in acute cerebral thromboembolism[J].Curr Med Res Opin,2002,18(suppl 2):s44.
  • 4Ohman EM,Harring RA,Cannon CP,et al.Intravenous thrombolysis in acute myocardial infarction[J].Chest,2001,119:253.
  • 5Wang P,Zhang J,Sun Z,et al.Catalytic and fibrinolytic properties of recombinant urokinase plasminogen activator from E.coli,mammalian,and yeast cells[J].Thromb Res,2000,100(5):461.
  • 6Lenich C,Pannell R,Henkin J,et al.The influence of glycosylation on the catalytic and fibrinolytic properties of pro-urokinase[J].Thromb Haemost,1992,68(5):539-544.
  • 7Weaver WD,Hartmann JR,Anderson JL,et al.New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction.Prourokinase study group[J].J Am Coll Cardiol,1994,24(5):1242-1248.
  • 8Wang P,Zhang J,Sun ZY,et al.Glycosylation of prourokinase by Pichia pastoris impairs enzymatic activity but not secretion[J].Protein Expression and Purification,2000,20:179-185.
  • 9杨波,李天德,胡显文.急性心肌梗死的静脉溶栓治疗[J].生物技术通讯,2005,16(1):100-104. 被引量:12

二级参考文献28

  • 1Modi NB, Eppler S, Breed J, et al. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction[J]. Thromb Haemost, 1998,79:134
  • 2Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial[J]. Circulation, 1998,98:2805
  • 3De Lemos JA, Antman EM, Giugliano RP. Comparison of a 60-versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarc-tion[J]. Am J Cardiol, 2000,86:1235
  • 4Roe MT, Ohman EM, Maas ACP, et al. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion[J]. J Am Coll Cardiol, 2001,37:9
  • 5Gurwitz JH, Gore JM, Goldberg R J, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction: participants in the National Registry of Myocardial Infarction 2[J]. Ann Intern Med, 1998,129:597
  • 6Trial of abciximab with and without low-dose reteplase for acute myocardial infarction: strategies for Patency Enhancement in the Emergency Department (SPEED) Group[J]. Circulation,2000,101:2788
  • 7The COBALT Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction[J]. N Engl J Med, 1997,337:1124
  • 8Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients[J]. JAMA, 2000,277:307
  • 9Alexander JH, A1-Khatib S, Cantor W, et al. Highlights from the American College of Cardiology 48th Annual Scientific Sessions,March 7 to 10, 1999[J]. Am Heart J, 1999,138:175
  • 10Van de Werf F, Cannon CP, Luyten A, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT- 1 trial[J]. Am Heart J,1999,137:786

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部